title: Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study.
abstract: Mobilized allogeneic PBPC are increasingly used instead of BM for allogeneic stem cell grafting. Although the short-term safety profile of recombinant human (rh)G-CSF seems acceptable, only minimal data on long-term safety are available. We therefore reviewed data on 171 sibling donors (M/F: 98/73) with respect to side effects of rhG-CSF and PBPC collection and impact on quality of life (QoL) and health status. In a cross-sectional study, we investigated the actual QoL and health status of the donors as well as the need for medical treatment since PBPC donation by a questionnaire that was sent to 151 donors. Ninety-five (64%) of the addressed donors responded to the questionnaire, but only 69 (46%) of them reported on their actual health status and QoL, which was good to very good in the majority of them. Two donors developed malignancies in the post-donation course. In general, PBPC collection after rhG-CSF mobilization was well tolerated by the responding donors. Although the reported events in medical history after PBPC donation do not seem to be associated with rhG-CSF administration or the collection procedure, a lifelong follow-up of donors should be obligatory.
authors.affiliation: Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria. gerda.leitner@meduniwien.ac.at
authors.forename: G C
authors.initials: GC
authors.lastname: Leitner
authors.forename: K
authors.initials: K
authors.lastname: Baumgartner
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.forename: D
authors.initials: D
authors.lastname: Biener
authors.forename: H T
authors.initials: HT
authors.lastname: Greinix
authors.forename: P
authors.initials: P
authors.lastname: Hoecker
authors.forename: N
authors.initials: N
authors.lastname: Worel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002469:Cell Separation; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology*; D006304:Health Status; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D012038:Regeneration; D012189:Retrospective Studies; D014019:Tissue Donors / Q000523:psychology*
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor